Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zinc & ADHD

This article was originally published in The Tan Sheet

Executive Summary

"Zinc as a supplementary medication might be beneficial in the treatment of children with attention-deficit hyperactivity disorder" who are being treated with methylphenidate, Shanin Akondzadeh, Tehran University of Medical Sciences, et al. conclude in a study recently published in BioMed Central. The 44 children studied in the six-week double-blind, placebo-controlled trial were given either methylphenidate 1 mg/kg/day plus zinc sulfate 55 mg or the same dose of methylphenidate plus placebo. Patients were assessed by a child psychiatrist at baseline, 14, 28 and 42 days. Parent and Teacher ADHD rating scale, which was the principal measure of the outcome, improved with zinc-sulfate. "Further investigations and different doses of zinc are required to replicate these findings in children with ADHD," authors state...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel